Maintenance treatment for hepatitis B-related lymphoma after initial therapy
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether the drug chidamide, taken after initial successful treatment, can help prevent relapse in people with a type of lymphoma (diffuse large B-cell lymphoma) who also have chronic hepatitis B. Participants must have achieved complete remission after six cycles of standard chemotherapy (R-CHOP).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with diffuse large B-cell lymphoma that is CD20-positive and have hepatitis B infection (positive for HBsAg, HBV DNA above 2000 IU/mL, or evidence of chronic infection).
- You have not received any prior treatment for lymphoma (except for biopsy or emergency radiation).
- You completed 6 cycles of R-CHOP chemotherapy and reached complete remission, confirmed by scans and possibly bone marrow biopsy.
- You are in generally good health, with adequate blood counts, kidney function, and liver function, and you can perform daily activities (ECOG 0-2).
- You are willing to use effective birth control if needed, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of the targeted drug chidamide with a gentler chemotherapy (R-mini CHOP) followed by maintenance therapy for people aged 70 or older with a specific type of DLBCL that has both MYC and BCL2 proteins. It aims to improve outcomes while reducing side effects.
This study tests a new medicine called Hepalatide for people with chronic hepatitis D, a serious liver infection. It aims to see if the drug can reduce the virus and improve liver health. You may be eligible if you have both hepatitis B and D and are on stable hepatitis B treatment.
This trial tests a low-dose chemotherapy pill (chidamide) for people with a certain high-risk type of DLBCL that still has signs of cancer in the blood after initial treatment. The goal is to keep the cancer from coming back.
This trial tests chidamide (a targeted medicine that affects how cells manage gene activity) in people whose peripheral T-cell lymphoma has come back or did not respond to treatment. It may help shrink measurable tumors and control the disease after prior therapies.
This study tests a maintenance drug called chidamide, which may help keep your T-cell leukemia or lymphoma from returning after a stem cell transplant. You will take this drug as a pill to see if it extends the time you stay cancer-free.
This trial tests adding chidamide to standard chemotherapy (R-CHOP) for people newly diagnosed with a specific subtype of diffuse large B-cell lymphoma. It may help improve outcomes for those whose cancer cells have high levels of MYC and BCL2 proteins.
Hear when a new Diffuse Large B-Cell Lymphoma (DLBCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.